Hexavalent Vaccines in India: Current Status

被引：7
作者：
Chitkara, Amar Jeet [1 ]
Parikh, Raunak [2 ]
Mihalyi, Attila [3 ]
Kolhapure, Shafi [2 ]
机构：
[1] Max Superspecial Hosp, Dept Pediat, Delhi, India
[2] Glaxo Smith Kline Biol SA, Mumbai, Maharashtra, India
[3] Glaxo Smith Kline Biol SA, Wavre, Belgium
来源：
INDIAN PEDIATRICS | 2019年 / 56卷 / 11期
关键词：
Combination vaccines; Acellular Vaccine; Immunization; Pertussis; PNEUMOCOCCAL CONJUGATE VACCINE; ACELLULAR PERTUSSIS-VACCINE; 3-DOSE PRIMARY VACCINATION; DTPA-HBV-IPV/HIB; ROUTINE INFANT; B VACCINE; COMBINATION VACCINES; IMMUNOGENICITY; SAFETY; IMMUNIZATION;
D O I：
10.1007/s13312-019-1651-y
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Hexavalent vaccines containing diphtheria, tetanus, pertussis, Haemophilus influenzae type b, poliomyelitis, and hepatitis B virus antigens have the potential to be used for the primary series in India (6, 10, 14 weeks of age) and the toddler booster dose. Three hexavalent vaccines are available in India: DTwP-Hib/HepB-IPV (wP-hexa), DTaP-IPV-HB-PRPT(2aP-hexa), and DTaP-HBV-IPV/Hib (3aP-hexa). In the three published phase-3 Indian studies, pertussis 'vaccine response' rates 1 month after a 6-10-14-week primary series were 68.4-75.7% for wP-hexa, 93.8-99.3% for 2aP-hexa, and 97.0-100% for 3aP-hexa; seroprotection rates for the other five antigens were 88.2-100%, 49.6-100%, and 98.6-100%, respectively. Studies outside India show: good immunogenicity/safety after boosting dosing; immune persistence to age 4.5 years (2aP-hexa), 7-9 years (3aP-hexa) (all antigens), and 9-10 and 14-15 years, respectively (hepatitis B); and successful co-administration with other vaccines. Hexavalent vaccines could reduce the number of injections, simplify vaccination schedules, and improve compliance.
引用
收藏
页码：939 / 950
页数：12
相关论文
共 65 条
[41]   Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review [J].
Patterson, Jenna ;
Kagina, Benjamin M. ;
Gold, Michael ;
Hussey, Gregory D. ;
Muloiwa, Rudzani .
VACCINE, 2018, 36 (40) :6007-6016
[42]  
Prymula R, 2018, PEDIAT INFECT DIS J
[43]   A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I) Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB [J].
Prymula, Roman ;
Esposito, Susanna ;
Zuccotti, Gian Vincenzo ;
Xie, Fang ;
Toneatto, Daniela ;
Kohl, Igor ;
Dull, Peter M. .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) :1993-2004
[44]  
Public Health England, HEX DTAP IPV HIB HEP
[45]   Key roles of adjuvants in modern vaccines [J].
Reed, Steven G. ;
Orr, Mark T. ;
Fox, Christopher B. .
NATURE MEDICINE, 2013, 19 (12) :1597-1608
[46]   Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: The Italian experience [J].
Salmaso, S ;
Mastrantonio, P ;
Tozzi, AE ;
Stefanelli, P ;
Anemona, A ;
degli Atti, MLC ;
Giammanco, A .
PEDIATRICS, 2001, 108 (05) :E81
[47]  
Sanofi Pasteur, HEX SUMM PROD CHAR
[48]   Efficacy of acellular pertussis vaccine in early childhood after household exposure [J].
Schmitt, HJ ;
vonKonig, CHW ;
Neiss, A ;
Bogaerts, H ;
Bock, HL ;
SchulteWissermann, H ;
Gahr, M ;
Schult, R ;
Folkens, JU ;
Rauh, W ;
Clemens, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (01) :37-41
[49]   Long-term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy [J].
Schwarz, Tino F. ;
Behre, Ulrich ;
Adelt, Thomas ;
Donner, Matthias ;
Suryakiran, Pemmaraju V. ;
Janssens, Winnie ;
Mesaros, Narcisa ;
Panzer, Falko .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (01) :235-241
[50]   A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine In Senegal [J].
Simondon, F ;
Preziosi, MP ;
Yam, A ;
Kane, CT ;
Chabirand, L ;
Iteman, I ;
Sanden, G ;
Mboup, S ;
Hoffenbach, A ;
Knudsen, K ;
Guiso, N ;
Wassilak, S ;
Cadoz, M .
VACCINE, 1997, 15 (15) :1606-1612
1234567